(Updated - September 30, 2019 10:22 AM EDT)

H.C. Wainwright analyst Joseph Pantginis downgraded Dova Pharmaceuticals Inc (NASDAQ: DOVA) from Buy to Neutral following acquisition with a price target of $27.50 (from $45.00).

For an analyst ratings summary and ratings history on Dova Pharmaceuticals Inc click here. For more ratings news on Dova Pharmaceuticals Inc click here.

Shares of Dova Pharmaceuticals Inc closed at $20.19 yesterday.

Downgrades